Rotigotine Improves Restless Legs Syndrome: A 6-Month Randomized, Double-Blind, Placebo-Controlled Trial in the United StatesHENING, Wayne A; ALLEN, Richard P; FICHTNER, Andreas et al.Movement disorders. 2010, Vol 25, Num 11, pp 1675-1683, issn 0885-3185, 9 p.Article

Comparing different salt forms of rotigotine to improve transdermal iontophoretic deliveryACKAERT, O. W; EIKELENBOOM, J; WOLFF, H. M et al.European journal of pharmaceutics and biopharmaceutics. 2010, Vol 74, Num 2, pp 304-310, issn 0939-6411, 7 p.Article

Antidepressant properties of rotigotine in experimental models of depressionBERTAINA-ANGLADE, Valerie; LA ROCHELLE, Christophe Drieu; SCHELLER, Dieter K. A et al.European journal of pharmacology. 2006, Vol 548, Num 1-3, pp 106-114, issn 0014-2999, 9 p.Article

Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson diseaseWATTS, R. L; JANKOVIC, J; WATERS, C et al.Neurology. 2007, Vol 68, Num 4, pp 272-276, issn 0028-3878, 5 p.Article

Transdermal rotigotine : Double-blind, placebo-controlled trial in parkinson diseaseJANKOVIC, Joseph; WATTS, Ray L; MARTIN, Wayne et al.Archives of neurology (Chicago). 2007, Vol 64, Num 5, pp 676-682, issn 0003-9942, 7 p.Article

Rotigotine-induced nail dyschromia in a patient with Parkinson diseaseTEIVE, Hélio A. G; MUNHOZ, Renato P.Neurology. 2011, Vol 76, Num 18, issn 0028-3878, p. 1605Article

Clinical studies with transdermal rotigotine in early Parkinson's diseasePOEWE, W; LEUSSI, F.Neurology. 2005, Vol 65, Num 2, pp S11-S14, issn 0028-3878, SUP1Article

A controlled trial of Rotigotine monotherapy in early Parkinson's DiseaseGROUP, The Parkinson.Archives of neurology (Chicago). 2003, Vol 60, Num 12, pp 1721-1728, issn 0003-9942, 8 p.Article

Efficacy, safety and risk of augmentation of rotigotine for treating restless legs syndromeINOUE, Yuichi; HIRATA, Koichi; HAYASHIDA, Kenichi et al.Progress in neuro-psychopharmacology & biological psychiatry. 2013, Vol 40, pp 326-333, issn 0278-5846, 8 p.Article

Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in SD ratsLIANG YE; XIAOLIN GUAN; JINGWEI TIAN et al.Food and chemical toxicology. 2013, Vol 56, pp 81-92, issn 0278-6915, 12 p.Article

Advanced Parkinson disease treated with rotigotine transdermal system PREFER StudyLEWITT, Peter A; LYONS, Kelly E; PAHWA, Rajesh et al.Neurology. 2007, Vol 68, Num 16, pp 1262-1267, issn 0028-3878, 6 p.Article

Continuous rotigotine administration reduces dyskinesia resulting from pulsatile treatment with rotigotine or L-DOPA in MPTP-treated common marmosetsSTOCKWELL, K. A; SCHELLER, D. K. A; SMITH, L. A et al.Experimental neurology (Print). 2010, Vol 221, Num 1, pp 79-85, issn 0014-4886, 7 p.Article

Rotigotine Effects on Early Morning Motor Function and Sleep in Parkinson's Disease: A Double-Blind, Randomized, Placebo-Controlled Study (RECOVER)TRENKWALDER, Claudia; KIES, Bryan; KASSUBEK, Jan et al.Movement disorders. 2011, Vol 26, Num 1, pp 90-99, issn 0885-3185, 10 p.Article

Long-Acting Versus Standard Non-Ergot Dopamine Agonists in Parkinson's Disease: A Meta-Analysis of Randomized Controlled TrialsZHOU, Chang-Qing; LOU, Jing-He; ZHANG, Yu-Ping et al.CNS neuroscience & therapeutics (Print). 2014, Vol 20, Num 4, pp 368-376, issn 1755-5930, 9 p.Article

Comparison of the bioavailability and adhesiveness of different rotigotine transdermal patch formulationsELSHOFF, Jan-Peer; TIMMERMANN, Lars; SCHMID, Miriam et al.Current medical research and opinion. 2013, Vol 29, Num 12, pp 1657-1662, issn 0300-7995, 6 p.Article

Skin penetration and mechanisms of action in the delivery of the D₂-Agonist rotigotine from surfactant-based elastic vesicle formulationsHONEYWELL-NGUYEN, P. Loan; ARENJA, Sonia; BOUWSTRA, Joke A et al.Pharmaceutical research. 2003, Vol 20, Num 10, pp 1619-1625, issn 0724-8741, 7 p.Article

The effects of the dopamine agonist rotigotine on hemispatial neglect following strokeGORGORAPTIS, Nikos; MAH, Yee-Haur; WARD, Nick et al.Brain. 2012, Vol 135, pp 2478-2491, issn 0006-8950, 14 p., 8Article

Preparation of Rotigotine-Loaded Microspheres and Their Combination Use with L-DOPA to Modify Dyskinesias in 6-OHDA-Lesioned RatsAIPING WANG; LEXI WANG; KAOXIANG SUN et al.Pharmaceutical research. 2012, Vol 29, Num 9, pp 2367-2376, issn 0724-8741, 10 p.Article

Three-month subchronic intramuscular toxicity study of rotigotine-loaded microspheres in Cynomolgus monkeysJINGWEI TIAN; GUANGYING DU; XIAOBO CEN et al.Food and chemical toxicology. 2013, Vol 52, pp 143-152, issn 0278-6915, 10 p.Article

Influence of transdermal rotigotine on ovulation suppression by a combined oral contraceptiveBRAUN, Marina; EISHOFF, Jan-Peer; ANDREAS, Jens-Otto et al.British journal of clinical pharmacology. 2009, Vol 68, Num 3, pp 386-394, issn 0306-5251, 9 p.Article

Rotigotine Transdermal System for the Treatment of Parkinson's DiseasePHAM, David Q; NOGID, Anna.Clinical therapeutics. 2008, Vol 30, Num 5, pp 813-824, issn 0149-2918, 12 p.Article

Rotigotine in Parkinson's disease. CommentaryREYNOLDS, Neil A; WELLINGTON, Keri; EASTHOPE, Stephanie E et al.CNS drugs. 2005, Vol 19, Num 11, pp 973-984, issn 1172-7047, 11 p.Article

En bref : Rotigotine transdermique = In Brief: Transdermal Rotigotine (Neupro)The Medical letter on drugs and therapeutics (Edition française). 2012, Vol 34, Num 19, issn 0253-8512, p. 73Article

Spotlight on Rotigotine in Parkinson's DiseaseBALDWIN, Claudine M; KEATING, Gillian M.Drugs & aging. 2008, Vol 25, Num 2, pp 175-177, issn 1170-229X, 3 p.Article

Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson's diseaseSCHELLER, Dieter; STICHEL-GUNKEL, Christine; LÜBBERT, Hermann et al.Neuroscience letters. 2008, Vol 432, Num 1, pp 30-34, issn 0304-3940, 5 p.Article